Evidence map›Paper›PMID 40580227›Full record

ArticleMolecular biology reports2025

The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrence.

Ariane P Souza, Isabely M Silva, Beatriz G L Vacario, Alexsandro Koike, Rafael G Paz, Carolina Coradi, Emily M S Wrzesinski, Guilherme L Trigo, Andrea N C Simão, Marcell A B Lozovoy and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ariane P SouzaLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, 86057-970, Brazil.ORCID http://orcid.org/0000-0002-5428-311X
Isabely M SilvaLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, 86057-970, Brazil.ORCID http://orcid.org/0009-0007-7488-5760
Beatriz G L VacarioLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, 86057-970, Brazil.ORCID http://orcid.org/0000-0003-1181-7617
Alexsandro KoikeLondrina Cancer Hospital, Londrina, 86015-520, Brazil.ORCID http://orcid.org/0000-0002-4411-8524
Rafael G PazLaboratory of Tumor Biology, Health Sciences Center, State University of West Paraná (UNIOESTE), Francisco Beltrão, PR, 85605-010, Brazil.ORCID http://orcid.org/0009-0003-3666-2399
Carolina CoradiLaboratory of Tumor Biology, Health Sciences Center, State University of West Paraná (UNIOESTE), Francisco Beltrão, PR, 85605-010, Brazil.ORCID http://orcid.org/0000-0001-7702-2505
Emily M S WrzesinskiLaboratory of Tumor Biology, Health Sciences Center, State University of West Paraná (UNIOESTE), Francisco Beltrão, PR, 85605-010, Brazil.ORCID http://orcid.org/0009-0002-2565-4396
Guilherme L TrigoLaboratory of Research in Applied Immunology, Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Paraná, 86038-440, Brazil.ORCID http://orcid.org/0000-0002-2637-8998
Andrea N C SimãoLaboratory of Research in Applied Immunology, Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Paraná, 86038-440, Brazil.ORCID http://orcid.org/0000-0002-2073-6782
Marcell A B LozovoyLaboratory of Research in Applied Immunology, Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Paraná, 86038-440, Brazil.ORCID http://orcid.org/0000-0002-4023-9548
Roberta L GuembarovskiLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, 86057-970, Brazil.ORCID http://orcid.org/0000-0002-6291-8621
Carolina PanisLaboratory of Tumor Biology, Health Sciences Center, State University of West Paraná (UNIOESTE), Francisco Beltrão, PR, 85605-010, Brazil.ORCID http://orcid.org/0000-0002-0104-4369
Juliana Mara SerpeloniLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, 86057-970, Brazil. julianaserpeloni@uel.br.ORCID http://orcid.org/0000-0001-9846-5807

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 402364/2021-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 404610/2021-8Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 01
6 · The paper itself

Abstract

backgroundUrothelial bladder cancer (UBC) is the ninth most common cancer worldwide. It is essential to investigate factors that may affect susceptibility and determine the prognosis of UBC. IRF5 is an interferon regulatory factor that modulates cellular differentiation during immune responses and oncogenesis. METHODS AND

resultsThe frequency of the rs3757385 (T > G) variant in IRF5 was evaluated in 295 patients with UBC and 295 individuals without neoplasia in a Brazilian population. Nitric oxide metabolites (NOx) systemic levels and IRF5 expression in normal and tumoral bladder tissues were also evaluated, as was the interaction between these parameters and prognostic indicators. Bioinformatics analyses compared gene expression patterns with TCGA data. The polymorphism was not associated with susceptibility to UBC. The mutated allele (G) was associated with a decrease in the relapses in the genotypic (OR = 0.205) and dominant (OR = 0.380) models. Hypertensive individuals with TG (genotypic, OR = 0.079) or TG + GG (dominant model, OR = 0.184) had fewer muscle-invasive tumors. Polymorphism did not alter the plasmatic NOx levels. Higher IRF5 expression was observed in patients with at least one G allele, males, smokers, and alcoholics. Directly, NOx was not associated with the prognostic parameters; however, individuals with the G allele and high NOx levels showed protection against relapses.

conclusionOur study highlights the association between rs3757385 (G allele) and high plasmatic NOx levels as good prognostic factors in UBC.

Indexed as

Interferon Regulatory FactorsNeoplasm Recurrence, LocalNitric OxideUrinary Bladder NeoplasmsAgedAllelesBrazilFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotidePrognosisInterferon Regulatory FactorsIRF5 protein, humanNitric OxideInflammationInterferonNitric oxide metabolitesSingle nucleotide variantUrothelial cancer

Identifiers

PMID40580227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.